271
Views
14
CrossRef citations to date
0
Altmetric
Original Article

Utilization and dosage pattern of echinocandins for treatment of fungal infections in US hospital practice*

, , &
Pages 385-393 | Accepted 12 Nov 2008, Published online: 22 Dec 2008

References

  • Turner MS, Drew RH, Perfect JR. Emerging echinocandins for treatment of invasive fungal infections. Expert Opin Emerg Drugs 2006;11:231-50
  • Morris MI, Villmann M. Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm 2006;63:1693-703
  • Cancidas package insert. Whitehouse Station, NJ, USA: Merck & Co, Inc., 2005
  • McCormack PL, Perry CM. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 2005;65:2049-68
  • Mycamine package insert. Deerfield, IL, USA: Astellas Pharma US, Inc., 2008
  • Eraxis package insert. New York, NY, USA: Pfizer, Inc., 2006
  • Patterson TF, Kirkpatrick WR, Alexander B, et al. Efficacy and safety of caspofungin (CAS) in a real world clinical setting. Poster presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 17–20, 2007; Chicago, IL
  • Ota Y, Tatsuno K, Okugawa S, et al. Relationship between the initial dose of micafungin and its efficacy in patients with candidemia. J Infect Chemother 2007;13:208-12
  • Blanchette CM, Joshi AV, Szpalski M, et al. Comparison between spinal surgery blood transfusion services costs and associated treatment practices in the United States and Belgium. Curr Med Res Opin 2007;23:2793-804
  • McQuellon RP, Russell GB, Shen P, et al. Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin. Ann Surg Oncol 2008;15:125-33
  • Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995;20:1526-30
  • Pettengell K, Mynhardt J, Kluyts T, et al.; FK463 South African Study Group. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004;20:475-81

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.